Nordic Nanovector Release: Invitation To Conference Call For Updated Clinical Trial Results Reported At The International Conference On Malignant Lymphoma

Nordic Nanovector ASA (OSE: NANO) will host a conference call on Wednesday, 14 June at 1 pm CET to present updated results from its ongoing LYMRIT 37-01 Phase 1/2 clinical trial of Betalutin® in patients with relapsed/refractory indolent non-Hodgkin's lymphoma. These data will be presented at the International Conference on Malignant Lymphoma (ICML) on 14-17 June in Lugano, Switzerland.

The call is scheduled for Wednesday, 14 June 2017 at 1 pm CET. Please make sure to dial in 5-10 minutes prior to scheduled conference call start time using the number and confirmation code below:

The conference call presentation will be available at in the section: Investor Relations/Reports and Presentation/Presentation/2017 from 1 pm CET on 14 June 2017.

IR enquiries:
Tone Kvåle, Chief Financial Officer
Cell: +47-91-51-95-76

Media enquiries:
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-282-2948/+44-207-282-2949

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.

The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.

Further information about the Company can be found at

Back to news